917474-59-0

Basic information

• Product Name: 5-BOC-AMINOINDAZOLE
• Synonyms: 5-BOC-AMINOINDAZOLE;tert-butyl 1H-indazol-5-ylcarbamate
• CAS NO: 917474-59-0
• Molecular Formula: C12H15N3O2
• Molecular Weight: 233.27
• Mol File: 917474-59-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 357.7°C at 760 mmHg
• Flash Point: 170.1°C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 2.69E-05mmHg at 25°C
• Refractive Index: 1.642
• CAS DataBase Reference: 5-BOC-AMINOINDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BOC-AMINOINDAZOLE(917474-59-0)
• EPA Substance Registry System: 5-BOC-AMINOINDAZOLE(917474-59-0)

Safety Data

• Hazardous Substances Data: 917474-59-0(Hazardous Substances Data)

Usage

General Description

5-BOC-AMINOINDAZOLE is a chemical compound that is commonly used as a building block in organic synthesis. It is an indazole derivative that is protected with a BOC (tert-butoxycarbonyl) group, which can be removed under mild conditions to reveal the reactive amine group. 5-BOC-AMINOINDAZOLE has applications in pharmaceutical research and drug discovery, particularly in the synthesis of potential drug candidates and complex organic molecules. Additionally, it is also used as a reagent in the preparation of various heterocyclic compounds and as a precursor for the synthesis of biologically active compounds. Overall, 5-BOC-AMINOINDAZOLE is a versatile and valuable compound in organic chemistry with diverse applications in the field of medicinal and pharmaceutical chemistry.

InChI:InChI=1/C12H15N3O2/c1-12(2,3)17-11(16)14-9-4-5-10-8(6-9)7-13-15-10/h4-7H,1-3H3,(H,13,15)(H,14,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 19335-11-6 1H-indazol-5-ylamine 

Downstream Products

• 1338792-40-7 3-{5-[(m-tolylmethylsulfonyl)amino]-1H-indazol-3-yl}benzenesulfonamide 
• 1338792-58-7 3-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)propanamide 
• 1338792-63-4 2-(pyridin-2-yl)-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-65-6 2-(pyridin-4-yl)-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-74-7 N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-2-(o-tolyl)acetamide 
• 1338792-70-3 2-(2,6-diethylphenyl)-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338793-18-2 1-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)cyclopropanecarboxamide 
• 1338792-71-4 (±)-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)butanamide 
• 1338792-75-8 3-methyl-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)butanamide 
• 1338794-29-8 2-cyclopentyl-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338794-32-3 2-cyclohexyl-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-50-9 2-methoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338818-06-6 (S)-2-methoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 
• 1338792-51-0 (R)-2-methoxy-2-phenyl-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide 

Relevant articles and documents

1-(5-Carboxyindazol-1-yl)propan-2-ones as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase: bioisosteric replacement of the carboxylic acid moiety

Indazole-5-carboxylic acids with 3-aryloxy-2-oxopropyl residues in position 1 were previously reported to be potent dual inhibitors of cytosolic phospholipase A2α (cPLA2α) and fatty acid amide hydrolase (FAAH). In continuation of our structure-activity studies on cPLA2α and FAAH inhibitors, a number of derivatives of these substances characterized by bioisosteric replacement of the carboxylic acid functionality by inverse amides, sulfonylamides, carbamates and ureas were prepared. The biological evaluation of the obtained compounds showed that the carboxylic acid functionality of the lead compounds is of special importance for a pronounced inhibition of cPLA2α and FAAH.

The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents

The acetamido and carboxamido substituted 3-(1H-indazol-3-yl)benzenesulfonamides are potent TTK inhibitors. However, they display modest ability to attenuate cancer cell growth; their physicochemical properties, and attendant pharmacokinetic parameters, a

INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T